Print full article

Merck snags Elanco’s coccidiosis treatment for $55 million

The sale of Vecoxan marks Elanco’s third product divestment in North America this year

Suggested Veterinary Products

Elanco Animal Health has unloaded its proprietary oral drench treatment for coccidiosis in calves and lambs to Merck Animal Health in an all-cash deal totaling $55 million.

The divestment encompasses the worldwide rights to Elanco’s proprietary Vecoxan product. The deal, Elanco says, aims to advance the company’s recent acquisition of Bayer’s animal health business.

The divestment is one of several announced by Elanco this year. In January, the company sold the global rights for its proprietary treatment for canine otitis externa to Dechra Pharmaceuticals in an all-cash deal totaling $135 million. The following week, PetIQ, a pet medication and wellness company, purchased the U.S. rights of Elanco’s proprietary flea treatment tablets for $95 million. The company also recently announced the divestiture of the European Economic Area and U.K. rights for two products from Bayer’s portfolio.

In total, these divestures have generated approximately $425 million in pretax proceeds, Elanco says.

“As we look broadly at the Bayer animal health transaction, we are encouraged by the significant progress from a regulatory, financing, and integration planning perspective, as well as Bayer’s underlying market positioning and performance,” says Elanco CEO, Jeff Simmons. “We continue to work toward a mid-2020 close.”

Leave a Comment



Sign-up for your account with Veterinary Practice News. Your account gives you unlimited free access to our Newsletter Archives and our Digital Editions of Veterinary Practice News.
Please check the box below to confirm you would like to be added to Kenilworth Media’s various e-mail communications (includes e-newsletters, a survey now and then, and offers to the veterinarian industry*).

Leave this empty:

*We do not sell your e-mail address to 3rd parties, we simply forward their offers to you. Of course, you always have the right to unsubscribe from any communications you receive from us, should you change your mind in the future.